515 related articles for article (PubMed ID: 14727985)
1. Management of protease inhibitor-associated hyperlipidemia.
Penzak SR; Chuck SK
Am J Cardiovasc Drugs; 2002; 2(2):91-106. PubMed ID: 14727985
[TBL] [Abstract][Full Text] [Related]
2. Beyond low-density lipoprotein: addressing the atherogenic lipid triad in type 2 diabetes mellitus and the metabolic syndrome.
Nesto RW
Am J Cardiovasc Drugs; 2005; 5(6):379-87. PubMed ID: 16259526
[TBL] [Abstract][Full Text] [Related]
3. Micronised fenofibrate: an updated review of its clinical efficacy in the management of dyslipidaemia.
Keating GM; Ormrod D
Drugs; 2002; 62(13):1909-44. PubMed ID: 12215067
[TBL] [Abstract][Full Text] [Related]
4. Hyperlipidemia associated with protease inhibitor therapy.
Echevarria KL; Hardin TC; Smith JA
Ann Pharmacother; 1999; 33(7-8):859-63. PubMed ID: 10466916
[TBL] [Abstract][Full Text] [Related]
5. Risk-benefit of HMG-CoA reductase inhibitors in the treatment of HIV protease inhibitor-related hyperlipidaemia.
Chuck SK; Penzak SR
Expert Opin Drug Saf; 2002 May; 1(1):5-17. PubMed ID: 12904155
[TBL] [Abstract][Full Text] [Related]
6. Atorvastatin in the treatment of primary hypercholesterolemia and mixed dyslipidemias.
Yee HS; Fong NT
Ann Pharmacother; 1998 Oct; 32(10):1030-43. PubMed ID: 9793596
[TBL] [Abstract][Full Text] [Related]
7. Combination therapy with an HMG-CoA reductase inhibitor and a fibric acid derivative: a critical review of potential benefits and drawbacks.
Farnier M
Am J Cardiovasc Drugs; 2003; 3(3):169-78. PubMed ID: 14727929
[TBL] [Abstract][Full Text] [Related]
8. Drug treatment of combined hyperlipidemia.
Wierzbicki AS; Mikhailidis DP; Wray R
Am J Cardiovasc Drugs; 2001; 1(5):327-36. PubMed ID: 14728015
[TBL] [Abstract][Full Text] [Related]
9. A comparison of lovastatin, an HMG-CoA reductase inhibitor, with gemfibrozil, a fibrinic acid derivative, in the treatment of patients with diabetic dyslipidemia.
Bell DS
Clin Ther; 1995; 17(5):901-10. PubMed ID: 8595642
[TBL] [Abstract][Full Text] [Related]
10. Interactions between antiretroviral drugs and drugs used for the therapy of the metabolic complications encountered during HIV infection.
Fichtenbaum CJ; Gerber JG
Clin Pharmacokinet; 2002; 41(14):1195-211. PubMed ID: 12405866
[TBL] [Abstract][Full Text] [Related]
11. Micronised fenofibrate: a review of its pharmacodynamic properties and clinical efficacy in the management of dyslipidaemia.
Adkins JC; Faulds D
Drugs; 1997 Oct; 54(4):615-33. PubMed ID: 9339964
[TBL] [Abstract][Full Text] [Related]
12. Atherogenic dyslipidemia in HIV-infected individuals treated with protease inhibitors. The Swiss HIV Cohort Study.
Périard D; Telenti A; Sudre P; Cheseaux JJ; Halfon P; Reymond MJ; Marcovina SM; Glauser MP; Nicod P; Darioli R; Mooser V
Circulation; 1999 Aug; 100(7):700-5. PubMed ID: 10449690
[TBL] [Abstract][Full Text] [Related]
13. Strategies for minimizing hyperlipidemia after cardiac transplantation.
Kirklin JK; Benza RL; Rayburn BK; McGiffin DC
Am J Cardiovasc Drugs; 2002; 2(6):377-87. PubMed ID: 14727953
[TBL] [Abstract][Full Text] [Related]
14. Disorders of lipid metabolism in patients with HIV disease treated with antiretroviral agents: frequency, relationship with administered drugs, and role of hypolipidaemic therapy with bezafibrate.
Manfredi R; Chiodo F
J Infect; 2001 Apr; 42(3):181-8. PubMed ID: 11545549
[TBL] [Abstract][Full Text] [Related]
15. Hyperlipidemia associated with HIV protease inhibitor use: pathophysiology, prevalence, risk factors and treatment.
Penzak SR; Chuck SK
Scand J Infect Dis; 2000; 32(2):111-23. PubMed ID: 10826894
[TBL] [Abstract][Full Text] [Related]
16. A head-to-head comparison of the cost effectiveness of HMG-CoA reductase inhibitors and fibrates in different types of primary hyperlipidemia.
Perreault S; Hamilton VH; Lavoie F; Grover S
Cardiovasc Drugs Ther; 1997 Jan; 10(6):787-94. PubMed ID: 9110123
[TBL] [Abstract][Full Text] [Related]
17. Current and future treatment of hyperlipidemia: the role of statins.
Farnier M; Davignon J
Am J Cardiol; 1998 Aug; 82(4B):3J-10J. PubMed ID: 9737640
[TBL] [Abstract][Full Text] [Related]
18. Comparison in patients with type 2 diabetes of fibric acid versus hepatic hydroxymethyl glutaryl-coenzyme a reductase inhibitor treatment of combined dyslipidemia.
McLaughlin T; Abbasi F; Lamendola C; Leary E; Reaven GM
Metabolism; 2002 Oct; 51(10):1355-9. PubMed ID: 12370858
[TBL] [Abstract][Full Text] [Related]
19. Use of fibrates in the management of hyperlipidemia in HIV-infected patients receiving HAART.
Calza L; Manfredi R; Chiodo F
Infection; 2002 Jan; 30(1):26-31. PubMed ID: 11876511
[TBL] [Abstract][Full Text] [Related]
20. Fenofibrate in the treatment of dyslipidemia: a review of the data as they relate to the new suprabioavailable tablet formulation.
Najib J
Clin Ther; 2002 Dec; 24(12):2022-50. PubMed ID: 12581543
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
